Outset Medical, INC

Outset Medical, Inc. announced the departure of Executive Vice President Marc Nash, effective June 5, 2026.

Outset Medical, Inc. reported improved financial results for Q4 and full year 2025, driven by significant gross margin expansion and reduced operating expenses, alongside positive 2026 guidance.

Outset Medical, Inc. announced FDA 510(k) clearance for its next-generation Tablo platform, featuring enhanced cybersecurity and reliability, with shipping expected in Q2 2026.

Outset Medical, Inc. announced its unaudited fourth quarter and full-year 2025 revenue, alongside the appointment of Karen N. Prange to its Board of Directors.

Outset Medical reported third-quarter results, revising its 2025 revenue guidance downwards due to shifted timing for large customer opportunities.

Outset Medical reported robust second-quarter 2025 financial results, marked by significant revenue growth, improved gross margins, and reduced operating expenses, leading to raised full-year revenue guidance.

Outset Medical reports a net loss of $19.0 million for Q1 2026, reflecting ongoing operational restructuring and market challenges.

Outset Medical posted 3% revenue growth, a 510 bps gross margin expansion, and a sharply reduced quarterly loss while shoring up liquidity through debt refinancing and preferred equity conversion.

Outset Medical, Inc. reported a significant reduction in net losses and improved gross margins for the first half of 2025, driven by revenue growth and cost optimization efforts.

Outset Medical's Q1 2025 results show revenue growth, reduced operating expenses, and strategic financing moves including a new term loan and preferred stock issuance.

Outset Medical's Q3 2024 results show a decrease in revenue compared to the previous year, alongside ongoing restructuring and cost-cutting measures.

Outset Medical's Q2 2024 revenue decreased by 24% year-over-year, primarily due to lower console sales, while the company focuses on enterprise selling and cost optimization.

Outset Medical's 2024 10-K filing reveals a company navigating market headwinds while focusing on expanding its Tablo Hemodialysis System's reach and improving financial performance.

Outset Medical updates its 2020 Equity Incentive Plan and details executive compensation and severance agreements, including clawback provisions.

John L. Brottem, General Counsel of Outset Medical, Inc., reported the acquisition of 59,830 restricted stock units.

Renee Gaeta, Chief Financial Officer of Outset Medical, Inc., acquired 71,630 restricted stock units on June 26, 2026, as part of her compensation.

Outset Medical's Chair and CEO, Leslie Trigg, reported a significant grant of restricted stock units.

Director Patrick T. Hackett acquired 10,667 restricted stock units in Outset Medical, Inc. as part of a standard equity grant.

Director Kevin O'Boyle was granted 10,667 restricted stock units (RSUs) by Outset Medical, Inc. on June 4, 2026.

Outset Medical director Karen Prange was granted 10,667 restricted stock units as part of standard equity compensation.

Outset Medical has released its 2026 proxy statement detailing director elections, executive compensation, and the ratification of its independent auditor.

Outset Medical announces the appointment of Kevin OBoyle to its Board of Directors and the resignation of Dale Jones, effective May 14, 2025.

Outset Medical, Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on June 2, 2025, with key proposals including the election of directors, executive compensation approval, and amendments to equity incentive and employee stock purchase plans.

Outset Medical is asking stockholders to approve amendments to its equity incentive and employee stock purchase plans at the 2025 annual meeting to increase the number of shares available for issuance.

Outset Medical is holding a special meeting to seek stockholder approval for a share issuance related to a recent financing, a reverse stock split, and other related proposals.

Outset Medical, Inc. announces its 2024 Annual Meeting of Stockholders to be held virtually on May 29, 2024, with voting open until May 28, 2024.

BML Investment Partners, L.P. has filed a Schedule 13G, reporting beneficial ownership of 13.6% of Outset Medical, Inc.'s common stock as of May 15, 2026.

Woodline Partners LP has disclosed a beneficial ownership of 1.6% in Outset Medical, Inc., holding 292,437 shares as of March 31, 2026.

BML Investment Partners, L.P. has filed a Schedule 13G, reporting beneficial ownership of 2,196,701 shares, representing 11.8% of Outset Medical, Inc.'s common stock.

The Vanguard Group reports zero beneficial ownership in Outset Medical Inc. following an internal reporting realignment.

BML Investment Partners, L.P. has reported a 10.5% beneficial ownership stake in Outset Medical, Inc., holding 1,902,201 shares of common stock.

Bank of America Corporation has reported a 5.2% beneficial ownership stake in Outset Medical, Inc., holding 950,558 shares of common stock.